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Abstract
49,XXXXY pentasomy or Fraccaro’s syndrome is the most severe variant of Klinefelter’s syndrome (KS) affecting
about 1/85000 male births. The classical presentation is the triad: mental retardation, hypergonadotropic
hypogonadism and radio ulnar synostosis. Indeed, the reproductive function of Fraccaro’s syndrome is
distinguished from KS. Besides, Leydig cell tumors are described in cases of KS, but never documented in the
Klinefelter variants.
We describe a young adult of 22 years old who presented with hyper gonadotropic hypogonadism, delayed puberty
and bilateral micro-cryptorchidism. Chromosomal pentasomy was confirmed since infancy. Bilateral orchidectomy
revealed a unilateral well-circumscribed Leydig cell tumor associated with bilateral Leydig cell hyperplasia.
Inspired from reporting the first case of Leydig cell tumor in a 49,XXXXY patient, we summarize the particularities of
testicular function in 49,XXXXY from one side, and the risk and mechanisms of Leydig cell tumorigenesis in Klinefelter
variants on the other side. The histological destructions in 49,XXXXY testes and hypogonadism are more profound than
in Klinefelter patients, with early Sertoli, Leydig and germ cell destruction. Furthermore, the risk of Leydigioma
development in KS and its variants remains a dilemma. We believe that the risk of Leydigioma is much higher in KS
than the general population. By contrast, the risk could be lower in the Klinefelter variants with more than 3
supplementary X chromosomes, owing to an earlier and more profound destruction of Leydig cells rendering them
irresponsive to chronic Luteinizing hormone (LH) stimulation.
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Background
Klinefelter syndrome (47,XXY or KS) is the commonest
aneuploidy. It affects 1/650 male births (0.2 % of general
population). Besides, more severe, fortunately rare, aneu-
ploidies are also described; these include: 48,XXXY,
48,XXYY and 49,XXXXY. 48,XXYY affects 1/8000-1/
40,000 male deliveries, while 48,XXXY affects 1/50,000.
Pentasomy 49,XXXXY incidence is around 1/85000 male
births [1, 2]. A 49,XXXXY karyotype is thought to arise
from maternal non-disjunction during both stages of
meiosis, retaining all the X chromosomes within the oo-
cyte. The major endocrine issues of aneuploidies are
hyper gonadotropic hypogonadism, testicular degenera-
tive changes and the risk of testicular tumorigenesis.
Indeed, Leydig cell tumors or Leydigioma are occasion-
ally described in cases of KS, but never in the Klinefelter
variants.
The objectives of this article are: we document herein,
the first case of Leydig cell tumor associated with bilat-
eral Leydig cell hyperplasia in a 49,XXXXY patient. Fur-
thermore, we will review the particularities of testicular
function in 49,XXXXY from one side and the mecha-
nisms and Leydig cell tumorigenesis in Klinefelter
variants on the other side.
Case presentation
A young patient born in 1990 is followed up in our depart-
ment for hypogonadism. At birth, facial dysmorphism
characterized by microcephaly, hypertelorism, inclination
of the palpebral fissures, small broad-based nose, micro
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retrognathia and a clinodactyly of the 5th finger were no-
ticed immediately. A parasternal systolic murmur of left-
to-right shunt was audible. The karyotype of the patient
revealed 49,XXXXY aneuploidy. During his childhood,
mental retardation and delayed milestones were docu-
mented with walking at age of 3.5 years, pronouncing
words of two syllables at age of 21 months. At age of
15 years, he was described as a joyful teenager, who showed
a substantial anxiety for unusual situations. His language
was limited to about ten words. He was able to write his
name correctly, to copy a short text and to count up to ten.
Clinical examination revealed a bilateral testicular ecto-
pia and hypoplasia of the external genitalia. Musculoskel-
etal examination revealed scoliosis and bilateral radio
ulnar synostosis. Moderate hypotonia was also noticed
since his childhood, along with a significant fatigability.
At age of 13 years, puberty was absent (Tanner stage P1)
and hyper gonadotropic hypogonadism was confirmed.
The hormonal profile was in favour of early severe testicu-
lar failure (FSH 27 UI/L, LH 17 UI/L with undetectable
testosterone levels). Testosterone therapy (50 mg/3 weeks,
increased progressively to 125 mg/3 weeks) was initiated
at the age of 15 years. Skeletal age was 12.5 years. Testos-
terone levels were consequently normalized to 5.4 ng/ml
under the substitutive treatment, with FSH reduced to 9.2
UI/L and LH levels to 5.1 UI/L (normal levels: FSH 2.2-
9.8 UI/L; LH 1.8-7 UI/L).
Young adult, he measures 1.83 m and weighs 55 kg
with a slender silhouette. His testicles were impalpable.
An abdmino-pelvic tomography revealed both testicles
in the inguinal position (Fig. 1a).
Bilateral orchidectomy was realized in 2012. The
macroscopic examination reported right and left small
testicles (1.5x1 cm). Excised tissues were fixed using 4 %
paraformaldehyde (Sigma-Aldrich) and embedded in
paraffin. Microscopic examination after Hematoxylin/
Eosin staining (Sigma-Aldrich) on 5 μm tissue sections
revealed that fibrous involution replaced the seminifer-
ous tubules along with disappearance of Sertoli cells, as-
sociated with Leydig cell hyperplasia. No germ cells
were detected. A well-circumscribed right-sided Leydig
cell tumor was detected. The tumor was composed of
hexagonal eosinophilic cells. Lipofusceine grains were ob-
served without Reinke crystalloids. The nuclei were
rounded with small nucleoli (Fig. 1b). Calretinin immuno
staining (790-4467/Ventana Clone SP65) confirmed the
nature of the sex cord stromal tumor (Fig. 1c). The ap-
pearance was monomorphic, without any significant pro-
liferative activity (less than 1 %) (Fig. 1d). The proliferative
activity was evaluated by immuno staining with human
anti-Ki67 antibody (Ki67: 790-4286/Ventana Clone 30–9).
Immunohistochemistry for calretinin and Ki-67 was con-
ducted according to the manufacturer’s recommendations;
the slides were then counterstained with haematoxylin.
Two years post-orchidectomy computed scanner re-
vealed no metastases. Testosterone replacement ther-




Harry Klinefelter published a report on nine men with
testicular dysgenesis, elevated gonadotropins, micro
orchidism, azoospermia, and gynecomastia in 1942 [3].
The hallmark of KS is hyper gonadotropic hypogonad-
ism with testicular atrophy [4]. The diagnosis is usually
evoked in infants with delayed milestones [5], and in
male adults with sterility [6, 7].
49,XXXXY is the most severe form, accounting for
1.4-1.7 % of aneuploidies [2, 8, 9]. Described firstly in
1960 by Fraccaro, since then, we detected 176 cases in
the literature. Some authors distinguish specific charac-
teristics of this syndrome [1, 10, 11]. The classical pres-
entation is the triad: mental retardation, hypogonadism
and radio ulnar synostosis [2, 10–12]. Hypogonadism is
severe and frequently associated with genital anomalies,
which are characterized by micro penis, small testicles
and scrotum, cryptorchidism and genital ambiguity.
Gynecomastia is rare [10].
Some paradoxical features seem to be specific to
49,XXXXY; 49,XXXXY are usually shorter than the
general population [13, 14]. Microcephaly is found in
some children with 20 % reduction in cerebral volume
[15], which is more severe than Klinefelter patients
[16]. Focal neurological signs are possible, which are
related to demyelination [15]. Language acquisition is
late, and usually other alternatives of communication
are used in adult age [17]. We analysed 176 published
cases of 49,XXXXY in the literature. We noticed two
principal malformations in the published cases: cardiac
(22 patients, mostly patent ductus arteriosus) and uro-
genital (7 patients). The global mortality in aneuploidies
in general and in 49,XXXXY in particular, studied in de-
tails in 3518 patients of a British cohort included be-
tween 1958 and 2003 (48 cases of 49,XXXXY), was
elevated (SMR: 1.5-2) with congenital heart diseases,
epilepsy and pulmonary embolism as major causes of
mortality [8].
Indeed, our patient presented the classical triad of
49,XXXXY syndrome, which was associated with facial
dysmorphism, psychological troubles, mental retardation
and cardiac malformation. But, he had eunuchoid morph-
ology as in Klinefelter patients, which is rare for
49,XXXXY.
2. Testicular function in 49,XXXXY
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Indeed, the testicular anomalies are the hallmark of
aneuploidies, starting from birth and on-going to adult-
hood [18]. Histological destructions in 49,XXXXY testes
are more profound than Klinefelter patients. In contrast
to KS, micro orchidism occurs in almost all cases of
48,XXYY, 48,XXXY and 49,XXXXY, with adult testicular
volumes typically around 1–4 mL [14, 17].
In early adulthood, Klinefelter patients seem to enter
normally in the puberty, with incomplete development of
secondary sexual characters, but this is rare in the variants
which are characterized by absence of puberty [19]. The
endocrine profile of KS and the variants is characterized by
normal levels of gonadotropins, AMH and Inhibin B with
variable levels of testosterone in infancy [20–22]. In infants,
Leydig cells are normally sensitive to the proliferative effect
of LH but Sertoli cell sensitivity is questionable, post pu-
bertal Sertoli cell resistance to FSH is definite [23]. Hypo-
gonadism is more profound in the variants than the
classical 47,XXY syndrome. This is due to a more profound
testicular damage, associated with lower testosterone
levels, even in infancy leading to ambiguous genitalia. The
endocrine profile of aneuploidies is summarized in Table 1.
In our case, the hypogonadism was profound with no
initiation of puberty. Gynecomastia was absent indicat-
ing no any testosterone secretion to be aromatized. Tes-
ticular ectopia was moderate but associated with a
complete testicular fibrosis, with no germ or Sertoli cells
identified. Therefore, we suggest that the chromosomal
anomaly is responsible for early Sertoli and germ cell de-
terioration. Indeed, we suppose that the degree of
damage of Sertoli cells, their sensitivity to follicle stimulat-
ing hormone (FSH) and germ cell destruction in patients
with more than 3 X chromosomes is more profound. This
is supported by the evidence that the chance of fertility or
successful retrieval of gametes is limited to Klinefelter pa-
tients especially in mosaic forms than other aneuploidies.
On the other side, Leydig cell deterioration is tardive. This
is supported by the testicular decent even if incomplete
(dependent on Insulin like 3 and testosterone secreted
from foetal Leydig cells), Leydig cell hyperplasia (re-
sponsiveness to chronic Luteinizing hormone stimula-
tion from puberty) and the presence of steroidogenesis
in early puberty. Nevertheless, In comparison to 47,
XXY, Leydig cell deterioration seems to be more pro-
found and earlier in 49,XXXXY patients, as steroid
synthesis is negligible manifested by higher risk of am-
biguous genitalia and absent puberty.
3. Risk of Leydig cell tumors or Leydigioma
Testicular tumors are relatively rare, corresponding to
1 % of all human cancers [24]. Germ cell tumors and
sex cord stromal tumors constitute the two predomin-
ant types. Since 1960s, the incidence of testicular cancer
doubled in most of western countries [25]. Fortunately,
only 20 % of these tumors appear during infancy (5–10
years old) [26]. Leydig cell tumors or Leydigioma repre-
sent 0.8–3 % of all testicular tumors in adulthood and
4-9 % of childhood testicular tumors [27–29]. Most of
these tumors are benign, especially in infancy [30].
Fig. 1 Identification of a Leydigioma in a patient with 49,XXXXY karyotype with bilateral testicular ectopia. a Identification of 1 and 1.5 cm
diameter testes within the inguinal groin by computed tomography in adolescence. b Identification of a well circumscribed 2 mm diameter
tumor in the testis. Tumor cells are hexagonal, with round uniform prominent nuclei. The cytoplasm is eosinophilic, or slightly pale due to lipid
accumulation. Lipofuschine pigment is identified in steroid producing tumors. Some calcification and hyalinization of the stroma could be
identified. Reinke crystals, pathognomonic for Leydigioma are present in only 40 % of the cases. They were absent in this case. c Immuno
staining of the tumor by Calretinin, a specific marker of stroma cell tumors. d Ki67 immuno staining. the proliferative index is low in the
benign tumors
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Testicular cancers are clearly linked to undescended
testis, testicular dysgenesis syndrome (TDS) and infertil-
ity [31–38]. Malignancy occurs in 3.5–14.5 % of undes-
cended testis. Thus, a higher risk of testicular cancers in
Klinefelter patients and the other variants has been sup-
posed. Leydig cell tumors and/or hyperplasia are not un-
common findings during the histological examination of
human testicular biopsies, especially in patients with tes-
ticular atrophy, cryptorchidism, KS and androgen in-
sensitivity syndrome [39, 40]. Indeed, a Danish Study
published in 1995 (696 patients) and a British cohort of
3518 patients with Klinefelter variants including 48 pa-
tients with 49,XXXX, seem to be the most significant
publications to explore the tumor risk. They showed a
higher relative risk of mortality (RR = 1.5), but cancer re-
lated mortality was not different from the general popu-
lation [9, 41]. More specifically, the risk of testicular
cancers seemed to be equivocal to the general popula-
tion in these studies. Nevertheless, extra gonadal (mostly
mediastinal) germ cell tumors were more commonly re-
ported in patients with KS in comparison to the general
population, with a prevalence of 1 % [41–44]. Further-
more, in another study, Ahmad et al. measured the vol-
ume of Leydig cells histometrically on biopsies of 50
cases of KS; the mean volume was within normal limits
[45]. Meanwhile, it is important to mention that the first
two studies interested more specifically in cancer risk
and did not take in consideration the benign tumors or
hyperplasia and they were based on the data registries.
On the other hand, Ahmad et al. analysis was based on
retrospective data. By contrast, a recent Italian study
screened the testes of 40 Klinefelter patients by
ultrasound, magnetic resonance imaging and tumor
markers. Over 3 years of follow up, 30 % of patients pre-
sented with either cysts or nodules, which were below
1 cm. But, no clinical, biological and radiological argu-
ments for testicular cancer were identified. Moreover, no
biological/morphological differences between those with
or without a history of cryptorchidism were noticed [46].
More specifically, a French cohort was based on ultra-
sound screening the testes of 141 KS patients. 158 tes-
ticular nodules in 56 (40 %) patients were identified.
20 % of them had bilateral nodules. Indeed, only 12 pa-
tients (7.6 %) were operated and all of them suffered
from Leydig cell hyperplasia and/or Leydig cell tumors.
On the other side, the karyotype anomalies in testicular
tumor context are not well recognized; unfortunately,
most studies interested in the testicular tumors neglected
the karyotype of these patients [37, 47]. A French study of
45 tumors in infertile patients with 11 Leydig cell hyper-
plasia and 17 benign Leydig cell tumors, revealed that KS
was found in 10 patients. Indeed, 12 Leydig cell tumors
were identified in these ten patients and fortunately all
were benign [48].
We analysed the literature for the published cases of tes-
ticular tumors in aneuploidies, over nearly 4000 patients
with KS and its variants, we identified only 34 patients
with gonadal and extra gonadal tumors. 20 patients had
Leydig cell tumors, fortunately only two were malignant;
teratomas were the second most common tumors de-
scribed (Table 2).
Returning to our patient, this is the first case of benign
Leydigioma associated with bilateral Leydig cell hyper-
plasia in a Klinefelter variant. It is important to say that
Table 1 Chronological evolution of clinical, histological and hormonal parameters of Klinefelter variants. Eunuchoid morphology and
gynecomastia are absent in 49,XXXXY karyotype
Parameter Infancy Early puberty (12 years) MidPuberty Tanner Puberty Tanner
II-III III-IV
FSH N N ++ ++++
LH N N + +++
T - N or - + - - -
E2 N ++ ++ ++
Inhibin B N N - - - - - -
AMH N N - - - - -
INSL3 N N - - - - - -
Germ cells Degeneration begun Progressive degeneration Accelerated degeneration in early puberty - - - -
Presence of spermatogonia only




+, ++, +++, ++++: Mild, moderate, high, very high increase; −, − −, − − −: mild, moderate, severe decrease; − − − −: undetectable; N: Normal; FSH: Follicle
stimulating hormone; LH: Luteinizing Hormone; T: Testosterone; E2: 17β oestradiol, AMH: Anti-Müllarian hormone; INSL3: Insulin Like 3
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the literature today shows an equivocal or even a lower
risk of testicular tumors in KS in comparison to the gen-
eral population. Nevertheless, Leydigioma incidence is
possibly underestimated, as early preventive orchidec-
tomy is usually practiced; furthermore, no systemic
screening is consensual to detect such tumors. As we
reviewed above, 30 to 40 % of KS patients have testicular
masses on imaging. To-date the real incidence of Leydig
cell tumor in KS and its variants is difficult to be esti-
mated; we believe that the risk is much higher than the
general population. By contrast, the risk could be lower
in the Klinefelter variants with more than 3 supplementary
X chromosomes, owing to an earlier and more profound
destruction of Leydig cells rendering it irresponsive to
chronic Luteinizing hormone (LH) stimulation. That’s
why, no Leydig cell tumor is yet reported in the literature
(176 cases of 49,XXXXY).
4. Physiopathology of Leydig cell tumorigenesis
Undescended or ectopic testes are common in aneu-
ploidies (about 14-28 % of the cases, 6 times higher than
the male general population) [49, 50]. The peak age and
histological distribution of tumor in undescended testis
are similar to the scrotal testes. Most of the studies re-
ported germ cell tumors (more than 90 % of the tumors)
and rarely, Leydig cell tumors were described. Indeed,
the mechanisms are multiple and remain unclear. One
hypothesis is that cryptorchidism is not merely an in-
complete descent of the testis, but it reflects a general-
ized defect in embryogenesis and results in bilateral
dysgenetic gonads. The most compelling is that the risk
of testicular carcinoma is not limited to the undescended
testis, but it extends to the contralateral testis, even if it
is normally descended. Thus, the increased risk of car-
cinoma cannot be attributed only to the local environ-
mental factors, such as increased temperature in the
abdomen versus the scrotum [51, 52].
Epidemiological studies identified common risk factors
between infertility and testicular cancer. Hyper estro-
genic and hypo androgenic status are the most com-
monly accepted risk factors for testicular cancer and
infertility. Although cryptorchidism is a known risk of
testicular cancer and infertility, the risk of testicular
cancer among infertile men exceeds the frequency of
cryptorchidism in the same population [37].
Table 2 Reported cases of testis-related tumours in aneuploidies
References No. of Patients Karyotype Tumour type
Yoshida [89] One 47,XXY Germ cell tumour
Carroll [90] One 47,XXY Germ cell tumour
Sasagawa [91] Two 47,XXY Germ cell tumours
Baniel [92] One 47,XXY Benign epidermal cyst
Reddy [93] One 48,XXYY Seminoma
Isurugi [94] One 47,XXY Seminoma
Tada [95] One 47,XXY Teratoma
Stevens [96] One 47,XXY Bilateral teratoma
Matsuki [97] One 46,XX/47,XXY Mature Teratoma
Simpson [98] Two brothers 47,XXY Teratomas
Gustavson [99] Two 47,XXY Bilateral Teratomas
Ekerhovd [100] One 47,XXY Sertoli cell tumour
Lardennois [101] One 47,XXY Bilateral Leydig cell tumours
Soria [102] One 47,XXY Malignant Leydig cell tumour
Arduino [103] One 47,XXY Benign Leydig cell tumour
Dodge [104] One 47,XXY Benign Leydig cell tumour
Knyrim [105] One 47,XXY Malignant Leydig cell tumour
Poster [106] One 47,XXY Benign Leydig cell tumour
Okada [107] One 47,XXY Benign Leydig cell tumour
Westlander [108] One 47,XXY Leydig cell tumour
Heer [109] One 47,XXY Leydig cell tumour
Fishman [110] One 47,XXY Benign Leydig cell tumour
Miazlin [77] One 47,XXY Benign Leydig cell tumour
De Miguel [111] Five 47,XXY Leydig cell hyperplasia in all
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Many mechanisms and animal models explain how a
Leydigioma could develop, nevertheless, the causes re-
main heterogeneous. Although LH plays an important
role in Leydig cell proliferation, Leydig cell maturation
and proliferation is affected by many other paracrine
and endocrine signals, including anti müllerian hor-
mone, inhibin, and other growth factors. The classical
pathway was suggested since 1980 with chronic LH
stimulation which induced Leydig cell hyperplasia/aden-
oma in rats [53]. Furthermore, anti-androgen therapy or
androgen insensitivity syndrome inducing LH secretion re-
sulted in the same phenotype [40, 54]. This hypothesis was
confirmed with the description of activating mutations of
LH receptors. Indeed, LH receptor is a trans membrane G
protein coupled receptor, expressed on Leydig cells. Acti-
vating mutations of this receptor are reported and induce
precocious puberty [55]. The chronic and permanent hyper
activation of this receptor leads to inappropriate stimula-
tion of cAMP pathway and Leydig cell hyperplasia. This
mutation is usually found in children who present with
Leydig cell tumor, and frequently responsible for preco-
cious puberty [56–65]. Actually, Asp578His mutation was
identified in more than 50 % of children with Leydig cell
tumors (13/24 patients) (reviewed in [57]).
Besides, mice models of KS with 41,XXY karyotype
[66], are characterized by small testes with Leydig cell
hyperplasia [67]. This supports the role of chronic and
permanent LH stimulation in the physiopathology of
Leydig cell tumor [67, 68].
Leydig cell tumor/hyperplasia were also linked to
many other situations than aneuploidies; these include:
McCune-Albright syndrome, Carney complex, fumarate
hydratase and cyclin dependent kinase (CDK) mutations.
The first two syndromes are multi tumor syndromes af-
fecting the endocrine system, including Leydig cells.
Their physiopathology is near to that of Klinefelter
variants with the activation of LH pathway (Activating
mutations of α subunit of protein G (GNAS) for
McCune-Albright syndrome [69–72] and hyperactivity
of protein kinase A in Carney complex [73, 74]).
5. Management of Leydig cell tumors
Orchidectomy is indicated in cases of benign Leydig cell
tumors (single, unilateral, well circumscribed tumor with-
out hyper vascularization, necrosis, lithiasis or calcification
on ultrasound) [75–77]. Owing to the favourable course of
such usually small-sized tumors, some published studies
advocated conservative or testis-sparing surgery [78–82].
Such option does not seem to be associated with an in-
creased risk of recurrence. Conservative surgery seems to
be important for young patients with single testicle with pa-
ternity desire [83, 84]. Frozen sections largely help to de-
cide a more radical surgery or not [79, 82, 85]. The first 2
years of the diagnosis of malignant Leydig cell tumor are
the most crucial for the prognosis of the patients, however,
metastases up to 17 years post operation were also ob-
served [86]. More radical surgery with retroperitoneal gan-
glion removal, chemotherapy, and/or radiotherapy could
be used [30, 87, 88].
The dilemma of surgical choice is less advocated in
adult patients with KS associated with undescended
testis, advanced testicular failure or non-existence of fer-
tility challenge. These concerns are usually present in
Klinefelter variants. Thus, no benefits are awaited from
testis-sparing surgical procedures.
Conclusion
We present a case of 49,XXXXY sex polysomy, who shares
a number of characteristics of the other 176 patients cases
described in the literature, namely, hypogonadism with
cryptorchidism, facial dysmorphism, musculoskeletal and
cardiac malformations, and mental retardation seriously
affecting language skills. He presented with a benign
Leydig cell tumor. To our best knowledge, this is the first
case of testicular Leydig cell tumor described in a patient
affected by Fraccaro syndrome.
Even if it shares some characteristics with KS,
49,XXXXY syndrome has to be distinguished and be
considered as the most severe form. Hypogonadism is
severe, together with genital ambiguity and absent pu-
berty evoking an earlier and more profound Sertoli,
Leydig and germ cell destruction.
The risk of Leydig cell tumors in aneuploidies remains a
dogma; it seems to be similar to the general population.
Nevertheless, this incidence is possibly underestimated, as
early preventive orchidectomy is usually practiced; further-
more, no systemic screening is consensual to detect such
tumors. On the other side, karyotype study in patients with
Leydig cell tumor/hyperplasia is seldom realized and needs
to be more systematic. Finally, the most agreed physiopa-
thology is related to chronic LH stimulation of Leydig cells.
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